Cargando…
Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes
Oncolytic virotherapy is an emerging immunotherapeutic modality for cancer treatment. Oncolytic viruses with genetic modifications can further enhance the oncolytic effects on tumor cells and stimulate antitumor immunity. The oncolytic vaccinia viruses JX-594-GFP+/hGM-CSF (JX-GFP) and TG6002 are gen...
Autores principales: | Heinrich, B, Klein, J, Delic, M, Goepfert, K, Engel, V, Geberzahn, L, Lusky, M, Erbs, P, Preville, X, Moehler, M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5422459/ https://www.ncbi.nlm.nih.gov/pubmed/28496337 http://dx.doi.org/10.2147/OTT.S126320 |
Ejemplares similares
-
Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer
por: Béguin, Jérémy, et al.
Publicado: (2020) -
Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs
por: Béguin, Jérémy, et al.
Publicado: (2021) -
Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs
por: Béguin, Jérémy, et al.
Publicado: (2020) -
The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism
por: Foloppe, Johann, et al.
Publicado: (2019) -
Oncolytic virotherapy with intratumoral injection of vaccinia virus TG6002 and 5-fluorocytosine administration in dogs with malignant tumors
por: Béguin, Jérémy, et al.
Publicado: (2023)